Study guide
16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
AACVPR CCRP Certified Cardiac Rehab Professional Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & Cardiac Rehabilitation Foundations
1.1 AACVPR CCRP Credential, Exam Specifications & Core Competencies 1.2 Phases of Cardiac Rehabilitation & Clinical Delivery Models 1.3 Interdisciplinary Team Roles, Clinical Scope of Practice & Safety
2 Chapter 2: Cardiovascular Anatomy, Physiology & Pathology
2.1 Cardiac Anatomy, Coronary Circulation & Hemodynamics 2.2 Atherosclerosis Pathogenesis, Acute Coronary Syndromes (ACS) & Revascularization 2.3 Heart Failure (HFrEF/HFpEF), Cardiomyopathies & Valvular Heart Disease 2.4 Electrical Interventions: Cardioversion, Catheter Ablation & Post-Procedure Rehabilitation
3 Chapter 3: Diagnostic Evaluation, ECG & Clinical Testing
3.1 Baseline Clinical Assessment & AACVPR Risk Stratification 3.2 12-Lead ECG Interpretation: Ischemia, Transmural Infarction & Conduction 3.3 Cardiac Arrhythmias, Conduction Blocks & Device Rhythms (Pacemakers/ICDs) 3.4 Graded Exercise Testing (GXT), Gas Exchange & Termination Criteria
4 Chapter 4: Patient-Centered Assessment: Education, Equity & Social Context
4.1 Learning Readiness: Health Literacy, Learning Styles & Communication Barriers 4.2 Social Determinants of Health, Culture & Spirituality in Cardiac Rehab 4.3 Sex- and Race-Based Differences in Cardiovascular Presentation & Outcomes 4.4 Substance Use Screening: Alcohol, Cannabis, Stimulants & Cardiac Risk
5 Chapter 5: Exercise Prescription & Aerobic Conditioning
5.1 FITT-VP Framework & Aerobic Exercise Intensity Calculation 5.2 Exercise Progression, Environmental Factors & Telemetry Monitoring Guidelines 5.3 High-Intensity Interval Training (HIIT) vs Moderate Continuous Training (MICT) 5.4 Home Exercise Program Design, Prescription & Independent Progression
6 Chapter 6: Exercise Physiology, Monitoring & Session Design
6.1 Health-Related Physical Fitness Components & Functional Capacity Testing 6.2 Acute Cardiovascular Responses to Aerobic Exercise: METs, Rate Pressure Product & VO₂ 6.3 Chronic Training Adaptations in Cardiac Patients 6.4 Structuring the Exercise Session: Warm-Up, Conditioning & Cool-Down 6.5 ECG Telemetry Setup: Skin Preparation, Electrode Placement & Artifact Troubleshooting 6.6 Pulse Oximetry, Exertional Desaturation & Supplemental Oxygen Titration
7 Chapter 7: Resistance, Flexibility & Exercise Safety
7.1 Resistance Training Guidelines, Hemodynamics & Sternal Precautions 7.2 Flexibility, Neuromotor Training & Special CR Populations 7.3 Exercise Contraindications, Adverse Signs/Symptoms & Emergency Protocols
8 Chapter 8: Physical Activity Counseling & Behavior Change
8.1 Physical Activity Guidelines, Sedentary Physiology & NEAT 8.2 Behavioral Change Theories: Transtheoretical Model & Social Cognitive Theory 8.3 Motivational Interviewing Principles & Resolving Ambivalence 8.4 SMART Goal Setting, Activity Tracking & Relapse Prevention
9 Chapter 9: Physical Activity Assessment & Real-World Activity Counseling
9.1 Physical Activity vs Exercise: Assessment Instruments, Logs & Wearables 9.2 Metabolic Requirements of Daily Life: Occupational, Recreational & Sexual Activity 9.3 Environmental & Situational Risk: Heat, Cold, Altitude, Air Quality & High-Risk Activities 9.4 Upper- vs Lower-Body Physiologic Demands & Modality Selection
10 Chapter 10: Hypertension & Blood Pressure Regulation
10.1 2017 ACC/AHA Hypertension Classification & Cardiovascular Risk 10.2 Antihypertensive Pharmacology & Exercise Hemodynamics 10.3 Exertional Blood Pressure Dynamics, Exertional Hypotension & Crisis 10.4 Home Blood Pressure Monitoring, Sodium Restriction & Lifestyle Interventions 10.5 Blood Pressure Measurement Technique, Device Validation & Renal Protection
11 Chapter 11: Diabetes Mellitus & Metabolic Regulation
11.1 Diabetes Pathophysiology, Diagnostic Criteria & Glycemic Targets 11.2 Antidiabetic Pharmacotherapy (Insulin, Sulfonylureas, SGLT2i, GLP-1 RA) 11.3 Exercise-Induced Hypoglycemia Management (Rule of 15) & Hyperglycemia 11.4 Diabetic Complications & Exercise Adaptations (Autonomic & Peripheral Neuropathy) 11.5 Blood Glucose Self-Monitoring, CGM Interpretation & Peri-Exercise Testing 11.6 Diabetic Foot Care, Skin Integrity & Footwear Assessment
12 Chapter 12: Blood Lipid Management & Atherosclerosis Prevention
12.1 Lipid Metabolism, Atherogenic Lipoproteins & Advanced Lipid Testing 12.2 Statin Therapy, Dosing Intensity & Secondary Prevention Targets 12.3 Non-Statin Pharmacotherapies & Statin-Associated Muscle Symptoms (SAMS)
13 Chapter 13: Medical Nutrition Therapy & Dietary Patterns
13.1 Nutritional Assessment & Macronutrient Guidelines in Cardiovascular Disease 13.2 Cardioprotective Dietary Patterns: Mediterranean, DASH & Plant-Based 13.3 Dietary Lipids, Sodium, Soluble Fiber & Plant Stanols/Sterols 13.4 Clinical Scope: CR Professional Counseling Boundaries vs RD/RDN Referral
14 Chapter 14: Body Composition & Weight Management
14.1 Anthropometric Assessment: BMI, Waist Circumference & Obesity Paradox 14.2 Behavioral Weight Management, Energy Balance & Caloric Deficits 14.3 Anti-Obesity Pharmacotherapy (GLP-1/GIP) & Bariatric Surgery Considerations
15 Chapter 15: Tobacco Cessation Interventions
15.1 Cardiovascular Pathophysiology of Tobacco, Nicotine & Secondhand Smoke 15.2 Clinical Cessation Frameworks: The 5 A's & 5 R's Models 15.3 Pharmacotherapy for Nicotine Dependence: NRT, Varenicline & Bupropion 15.4 Behavioral Counseling, Coping Strategies & Relapse Prevention
16 Chapter 16: Psychosocial Health, Screening & Behavioral Support
16.1 Psychosocial Risk Factors & Prognostic Impact in Heart Disease 16.2 Validated Screening Instruments: PHQ-9, GAD-7 & Administration 16.3 Evidence-Based Interventions: Stress Management, CBT Principles & Social Support 16.4 Crisis Protocols, Suicidal Ideation & Mental Health Referral Pathways 16.5 Psychotropic Pharmacology & Cardiac Safety 16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
17 Chapter 17: Regulatory Compliance, Documentation & Program Outcomes
17.1 CMS Coverage Guidelines, Qualifying Diagnoses & Practitioner Supervision 17.2 Individualized Treatment Plan (ITP) Components, 30-Day Updates & Goals 17.3 AACVPR Outcome Domains & Program Certification Performance Measures 17.4 Program Certification, Quality Improvement & Medical Emergency Preparedness
16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
Key Takeaways Explain This Topic AI
Obstructive sleep apnea is highly prevalent in cardiovascular disease and is associated with resistant hypertension, atrial fibrillation, heart failure, and stroke; STOP-BANG is the standard screening tool.
A STOP-BANG score of 3 or higher indicates intermediate risk and 5 or higher indicates high risk for obstructive sleep apnea, warranting referral for sleep evaluation.
Cognitive behavioral therapy for insomnia is first-line treatment for chronic insomnia and is preferred over hypnotic medication, which carries fall and dependence risk in cardiac populations.
NSAIDs raise blood pressure, cause fluid retention, increase cardiovascular events, and can blunt the antiplatelet effect of aspirin when ibuprofen is taken before it.
Omeprazole and esomeprazole inhibit CYP2C19 and reduce clopidogrel activation, so pantoprazole is generally preferred when a proton pump inhibitor is needed with clopidogrel.
Last updated: September 2026
16.6 Sleep Disturbance, Chronic Pain & Somatic Comorbidity in Psychosocial Management
Note
Blueprint anchor : Domain 8 (Psychosocial Management), task 8.9 — Educate on the relationship between psychosocial considerations and other health issues (e.g., GI, chronic pain, impaired immune response, sleep disturbances) .
Depression, poor sleep, chronic pain, and gastrointestinal symptoms cluster together and reinforce one another. A patient who is not sleeping is more depressed; a patient in pain exercises less and sleeps worse; untreated sleep apnea drives resistant hypertension and atrial fibrillation. Treating any one of these in isolation frequently fails, which is why the blueprint asks you to understand the connections.
Obstructive Sleep Apnea
OSA is strikingly common in cardiovascular populations and is frequently undiagnosed.
Cardiovascular consequences
Repetitive apneas produce intermittent hypoxemia, large intrathoracic pressure swings, arousals, and sympathetic surges. The downstream associations include:
- Resistant hypertension and a non-dipping nocturnal blood pressure pattern
- Atrial fibrillation , with higher recurrence after cardioversion and ablation when OSA is untreated
- Heart failure — both HFrEF and HFpEF
- Stroke , pulmonary hypertension, and nocturnal arrhythmia
- Insulin resistance and worsened glycemic control
- STOP-BANG screening
- Letter Item
- S Snoring loudly
- T Tired — daytime fatigue or sleepiness
- O Observed apnea by a bed partner
- P Pressure — treated hypertension
- B BMI greater than 35 kg/m²
- A Age over 50
- N Neck circumference greater than 40 cm
- G Gender — male
Score 0-2: low risk. 3-4: intermediate risk. 5-8: high risk. A score of 3 or higher warrants discussion and referral consideration; 5 or higher warrants referral for sleep evaluation. The Epworth Sleepiness Scale complements it by quantifying daytime sleepiness.
Important
A CR patient with resistant hypertension , recurrent atrial fibrillation , or excessive daytime sleepiness should be screened for OSA. Identifying it is one of the highest-value referrals a CR program makes, because treatment can improve blood pressure control and arrhythmia recurrence. For patients already on CPAP, ask about adherence — nightly hours of use — because prescribed therapy that sits in a closet delivers nothing, and common barriers such as mask fit, pressure intolerance, and nasal dryness are all solvable when reported.
Insomnia
Insomnia and depression are bidirectional : each causes and worsens the other, and insomnia is a risk factor for the development and recurrence of depression. Both short sleep (under about 6 hours) and long sleep are associated with adverse cardiovascular outcomes.
Important
Cognitive behavioral therapy for insomnia (CBT-I) is first-line treatment for chronic insomnia , recommended ahead of hypnotic medication. Its components — stimulus control, sleep restriction, cognitive restructuring, and sleep hygiene — produce durable benefit without the fall risk, cognitive impairment, and dependence associated with hypnotics and benzodiazepines in older cardiac patients.
Sleep hygiene counseling within CR scope: consistent sleep and wake times, a dark and cool bedroom, restricting the bed to sleep, limiting caffeine after midday and alcohol near bedtime (alcohol fragments sleep architecture despite hastening sleep onset), limiting screens before bed, and getting daytime light exposure. Regular exercise improves sleep quality , though some patients sleep worse when exercising vigorously close to bedtime and should shift sessions earlier.
Also consider that nocturnal dyspnea or orthopnea may represent heart failure rather than insomnia, that diuretic timing late in the day causes nocturia, and that nocturnal angina requires cardiac rather than sleep evaluation.
Chronic Pain
Chronic pain limits participation, worsens mood and sleep, and is frequently the reason a patient stops attending.
Analgesic cardiovascular safety
Warning
NSAIDs — ibuprofen, naproxen, diclofenac, celecoxib — carry substantial cardiovascular liability:
- Raise blood pressure and antagonize antihypertensive efficacy
- Cause sodium and fluid retention , precipitating heart failure decompensation
- Increase cardiovascular events , with the risk elevated in patients with established coronary disease
- Reduce renal perfusion , harmful with chronic kidney disease and with RAAS blockade plus a diuretic
Blunt aspirin's antiplatelet effect when ibuprofen is taken before aspirin ; if both are used, aspirin should be taken first with an appropriate interval
Acetaminophen is generally the preferred first-line oral analgesic in cardiac patients, within hepatic dose limits.
Opioids bring sedation, constipation, fall risk, and limited long-term benefit for chronic non-cancer pain, and a sedated patient on a treadmill is a safety issue. Note the pain-relevant psychotropics that overlap with the previous section: duloxetine for neuropathic pain and low-dose amitriptyline for neuropathic pain or sleep, the latter carrying orthostatic, anticholinergic, and QT concerns in cardiac patients.
Behavioral approach
Pain catastrophizing and fear-avoidance beliefs predict disability better than pain intensity does. The effective CR strategy is graded activity and pacing : start well below the flare threshold, progress on a time-based rather than pain-based schedule, and explicitly separate hurt from harm , since musculoskeletal discomfort during graded activity does not indicate tissue damage. Choose low-impact modalities and consider aquatic options where available.
Gastrointestinal Overlap
GERD mimics angina. Both produce substernal burning, both can radiate, and both may occur after meals. Never assume reflux in a patient with known coronary disease — evaluate as cardiac until proven otherwise, and note that relief with antacids does not exclude ischemia.
Stress and anxiety drive functional GI symptoms, and the gut-brain relationship is bidirectional.
Warning
PPI and clopidogrel interaction. Clopidogrel is a prodrug requiring CYP2C19 activation. Omeprazole and esomeprazole inhibit CYP2C19 , reducing clopidogrel's antiplatelet effect. Pantoprazole is generally preferred when a proton pump inhibitor is needed alongside clopidogrel. This interaction does not apply to prasugrel or ticagrelor, which do not depend on CYP2C19 activation.
Impaired Immune Response and Inflammation
Chronic psychological stress and depression are associated with elevated inflammatory markers including C-reactive protein and interleukin-6 , sympathetic and HPA-axis activation with cortisol dysregulation, impaired immune function and slower wound healing, and increased platelet reactivity. This inflammatory pathway is one of the principal proposed mechanisms linking depression to worse cardiovascular outcomes — depression is not merely a comorbid mood problem but a plausible biological contributor. Framing it this way for patients reduces stigma: treating depression is cardiac care.
Differentiating Fatigue
Fatigue is the common final pathway of nearly everything discussed here, and distinguishing causes changes management:
- Cause Distinguishing features
- Depression Anhedonia, guilt, worse in the morning, positive PHQ-9
- Obstructive sleep apnea Snoring, witnessed apnea, unrefreshing sleep, morning headache
- Heart failure Exertional dyspnea, orthopnea, edema, weight gain
- Anemia Pallor, tachycardia, exertional dyspnea
- Beta-blocker effect Temporal relation to initiation or dose increase, bradycardia
- Deconditioning Improves with training
- Hypothyroidism Cold intolerance, constipation, weight gain, bradycardia
- Realistic Clinical Scenario
Scenario : A 62-year-old man with atrial fibrillation recurring twice since ablation and blood pressure of 152/92 despite three antihypertensives reports profound daytime fatigue. He snores loudly, his wife has observed him stop breathing, his BMI is 37, neck circumference 44 cm, and he is 62 years old. His PHQ-9 is 11. He takes ibuprofen most days for knee osteoarthritis and omeprazole for reflux. He is on clopidogrel.
Analysis : His STOP-BANG score is 8 — snoring, tired, observed apnea, treated hypertension, BMI over 35, age over 50, neck over 40 cm, male — placing him at high risk for obstructive sleep apnea, which plausibly explains his resistant hypertension, his post-ablation atrial fibrillation recurrence, and his fatigue simultaneously. Two medication problems compound it: daily ibuprofen raises blood pressure, antagonizes his three antihypertensives, causes fluid retention, and adds cardiovascular risk; and omeprazole inhibits CYP2C19 , reducing activation of his clopidogrel and blunting its antiplatelet effect. His PHQ-9 of 11 indicates moderate depressive symptoms that both contribute to and result from the poor sleep.
Plan : Refer for sleep evaluation as the highest-yield action — a STOP-BANG of 8 with resistant hypertension and recurrent atrial fibrillation makes untreated OSA the likely unifying diagnosis. Report both medication issues to the prescriber with specifics: recommend substituting acetaminophen for daily ibuprofen within hepatic limits and switching omeprazole to pantoprazole to preserve clopidogrel activation, while leaving the decisions to the prescriber. Address the knee pain with a graded, low-impact, time-based progression that separates hurt from harm rather than pain-limited activity. Deliver sleep hygiene counseling and schedule his sessions earlier in the day. Refer for behavioral health evaluation given the PHQ-9 of 11, framing depression treatment as cardiac care, and re-administer the PHQ-9 at the 30-day update.